Menu
← Oncology Approval Tracker
FDA DECISION ·
Lynparza + abiraterone
olaparib + abiraterone + prednisone or prednisolone · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with metastatic castration-resistant prostate cancer and a deleterious or suspected deleterious BRCA mutation on an FDA-approved companion diagnostic.
LAMPGEN ANALYSIS
Why it matters
FDA limited this PARP inhibitor combination to the BRCA-defined group.
What research teams should watch
Confirm the companion diagnostic result and coordinate steroid, blood-count and blood-pressure monitoring.
PRIMARY RECORDS